Analyst firms · BofA Securities · KYMR
BofA Securities KYMR price target and rating history
Kymera Therapeutics Inc. (KYMR) · Health Care
BofA Securities rates Kymera Therapeutics Inc. (KYMR) Buy with a $51 price target, as of its latest action on Jun 2, 2025. It has published 4 rating actions on KYMR since September 2021, including 2 upgrades and 2 downgrades. Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.
- Current rating
- Buy
- Price target
- $51
- Median target, all firms
- $133
- Actions on KYMR
- 4
BofA Securities price target on KYMR
Every BofA Securities rating on KYMR
- Jun 2, 2025
- Jan 3, 2024
- Sep 10, 2021
- Sep 10, 2021
How other firms rate KYMR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $140 | Oct 9, 2026 |
| Wolfe Research | Outperform | $180 | Sep 10, 2026 |
| Deutsche Bank | Hold | $120 | Jul 30, 2026 |
| Canaccord Genuity | Buy | $106 | May 6, 2026 |
| Jefferies | Buy | Mar 16, 2026 | |
| Barclays | Overweight | $133 | Jan 28, 2026 |
Questions about BofA Securities and KYMR
- What is BofA Securities's price target for KYMR?
- BofA Securities's latest stated price target for Kymera Therapeutics Inc. (KYMR) is $51, from its action on Jun 2, 2025.
- What is BofA Securities's rating on KYMR?
- BofA Securities rates KYMR Buy, a bullish rating, as of Jun 2, 2025.
- When did BofA Securities last change its view on KYMR?
- On Jun 2, 2025, BofA Securities upgrades to Buy from Neutral, price target $51.
- How does BofA Securities's KYMR target compare with other analysts?
- Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.
More KYMR rating histories
All BofA Securities ratingsKYMR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.